BCL2 and glioblastoma: Having a similar IC50 value with a clinically available Bcl-2 inhibitor ABT-199, BAU-243 demonstrated a remarkable anti-proliferative effect on the cancer sub-population that is considered a true representative of tumor-initiating GBM stem-like cells.